Compounded vs Brand GLP-1: Cost & Tradeoffs

Compounded GLP-1s have typically cost far less than brand products, which is exactly why they exploded in popularity during the drug shortage. But "cheaper" came with real tradeoffs, and the 2025 resolution of the official FDA shortage reshaped what compounded products are even legal to make. As of mid-2026, the low-cost compounded route that defined the prior couple of years is far less available, and the status is still evolving and state-dependent.

This article focuses on the money: the real price gap, what the lower number did and did not include, and how the regulatory changes affect your wallet. It is general education, not medical, legal, or financial advice, and it does not endorse any way of sourcing medication. We deliberately do not list specific prices, because they change constantly. For the broader product comparison, see our companion piece, brand vs compounded GLP-1.

Why compounded GLP-1s were so much cheaper

A compounded medication is one prepared by a pharmacy rather than manufactured and packaged by the original drugmaker. During the official shortages, when the FDA declared semaglutide (2022) and later tirzepatide in short supply, compounding pharmacies were allowed under enforcement discretion to produce copies of the unavailable products.

The price gap had a few drivers. Compounded versions were not the patented finished product, so they sidestepped brand pricing. They were usually sold cash-pay rather than billed through insurance, which removed the coverage uncertainty that makes brand costs so variable. And they came as multi-dose vials drawn with a syringe rather than as prefilled pens, a cheaper format to produce.

The result was a compounded price that often landed well below brand list prices, which is what made it attractive to people whose insurance did not cover brand GLP-1s for weight management.

Compounded vs brand on cost and tradeoffs

The table below frames the economics alongside what the price difference reflected. Treat it as a discussion framework, not a recommendation toward either column, and remember the regulatory rows in particular keep changing.

Factor	Brand GLP-1	Compounded GLP-1
Typical cost	High list price; out-of-pocket depends on insurance	Historically lower cash-pay price; availability shifted after 2025
Insurance coverage	Varies; weight-management coverage inconsistent	Usually cash-pay, outside insurance
FDA oversight	Approved finished product, reviewed for quality	Not FDA-approved as a finished product
Consistency	Standardized concentration per the label	Concentration varies by pharmacy; same units can mean different mg
Dosing format	Prefilled pen, dose in mg	Vial drawn in units on an insulin syringe
Tracking complexity	Lower; dial a dose	Higher; log concentration plus units and mg per vial
Availability in 2026	Commercially available	Broad compounding no longer permitted post-shortage

Sources: FDA statements on compounding and GLP-1 supply; FDA shortage-resolution announcements (2024 to 2025); brand prescribing information.

What the lower price did not include

This is the honest core of the cost comparison. The compounded discount was never a pure apples-to-apples markup difference, because the cheaper product was a different thing.

A lower price on a compounded vial bought you a product without FDA approval behind it. That means it did not clear the agency's review for safety, efficacy, and manufacturing quality the way brand drugs did. It also carried more dosing-error risk: because compounded vials are drawn in units on an insulin syringe and the concentration is set by each pharmacy, the same unit reading can translate to a very different milligram dose depending on the vial. The FDA has flagged real-world dosing errors with compounded GLP-1s, including cases where patients drew far more than intended.

On top of that, many compounded prescriptions did not simply copy the brand drug. A large share added supplemental ingredients like B vitamins, and some used salt forms of the active ingredient rather than the base form in the brand product. So part of what the lower price reflected was a formulation that had not been studied as a finished product.

None of this makes the savings illusory for people who genuinely could not afford the brand. It means the price gap reflected a difference in oversight and standardization, not just a difference in markup. Our guide on GLP-1 units, mL, and mg explained covers why that unit-versus-mg literacy matters more with compounded vials.

The 2026 regulatory reality (read this carefully)

The biggest change to the cost equation is not a price; it is availability. The shortages that justified broad compounding have been declared resolved.

The FDA confirmed the semaglutide shortage resolved on February 21, 2025, with enforcement discretion for 503A pharmacies ending April 22, 2025 and for 503B outsourcing facilities on May 22, 2025. For tirzepatide, the shortage was declared resolved on December 19, 2024, with 503A facilities required to cease by February 18, 2025 and 503B facilities by March 19, 2025.

The practical result as of mid-2026 is that broad commercial compounding of semaglutide and tirzepatide is no longer permitted under the shortage provisions. Some limited individualized compounding may still occur where a prescriber documents a specific clinical need, but the large-scale cash-pay compounded market that drove the savings has contracted significantly.

A fair caution: this landscape continues to evolve, and details differ by state and facility type. Anything you read about compounded GLP-1 availability or pricing has a short shelf life, so verify the current status with your prescriber or pharmacist rather than acting on a snapshot.

How to weigh brand cost in 2026

With broad compounding curtailed, the practical cost question for most people is now about the brand product. Out-of-pocket cost there depends on whether your plan covers GLP-1s for your indication, what tier the drug sits on, and whether a manufacturer savings program applies. Weight-management coverage has been more inconsistent than diabetes coverage, which is a big reason two people on the same drug can pay wildly different amounts.

Because these numbers move, the useful step is to check directly: ask your pharmacy about your covered price for the brand, ask your insurer about prior authorization, and ask the manufacturer about any savings card. If cost is a barrier, that is a conversation to have openly with your prescriber, who may know about coverage pathways or alternatives.

If you are also weighing format as part of cost, our oral vs injectable GLP-1 comparison covers how newer pill options factor in.

The part that does not change with price: protect your muscle

Here is the thread that runs through every GLP-1 cost decision. The price you pay and the source you use affect your wallet and your logistics, but they do not change the body-composition math. Rapid weight loss on any GLP-1, brand or compounded, carries a risk of losing lean mass alongside fat. Research suggests roughly 25 to 40% of total weight lost on these drugs can come from lean mass, a category that includes water and organ mass, not only skeletal muscle.

Whichever route you choose for cost, the levers that protect muscle are identical: adequate protein, resistance training, and tracking body composition rather than just the scale. The full picture lives in our GLP-1 muscle loss complete guide.

This is also where dose-tracking discipline pays off regardless of price. A cheaper compounded vial demands more tracking care, not less, because of its variable concentration. Myo logs both brand pens and compounded vials in units and mg, so a budget compounded vial is recorded as precisely as a brand pen, right next to your protein and lean-mass data. That way cost never becomes an excuse for a sloppy dose record. Myo is a tracking and education tool, not medical advice, and it is not affiliated with any GLP-1 maker.

The bottom line

Compounded GLP-1s were cheaper for real reasons, but the discount reflected less oversight, more dosing-error risk, and sometimes a different formulation than the studied drug. The 2025 shortage resolution then curtailed the broad compounding that made those savings widely available, so in 2026 the cost conversation is mostly about brand coverage, savings programs, and what your plan will pay.

Let cost inform the decision, but do not let it override safety or the dose-tracking discipline either route demands. Verify the current regulatory status with your pharmacist, weigh the real out-of-pocket numbers with your prescriber, and keep your muscle-protecting habits steady no matter which column you land in.

References

FDA policies on compounding GLP-1s and supply stabilization: FDA drug alerts and statements, "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize."

Semaglutide shortage resolved February 21, 2025; 503A enforcement discretion ended April 22, 2025; 503B ended May 22, 2025: FDA announcements.

Tirzepatide shortage resolved December 19, 2024; 503A ceased February 18, 2025; 503B ceased March 19, 2025: FDA announcements; NCPA summary.

Dosing-error risk and added ingredients in compounded GLP-1s: FDA statements on compounded GLP-1 safety.

Brand product details: Ozempic, Wegovy, Mounjaro, and Zepbound prescribing information (accessdata.fda.gov).

Lean-mass share of weight lost on GLP-1s (~25-40%): SURMOUNT-1 body-composition substudy (DOM 2025, doi:10.1111/dom.16275); STEP 1 and SUSTAIN 8 DXA analyses.